US equities are ending the week with mixed sentiment. Stocks have been lower most of the week with Russia’s war and COVID-19 dampening investor outlook.
Oil down, gold down and Bitcoin (BTC) down.
Here are some of today’s trending stocks:
Medavail Holdings Inc (NASDAQ: MDVL)
Medavail Holdings Inc (NASDAQ: MDVL) is a tech-enabled pharmacy, serving customers via a self-service pharmacy, mobile application, kiosk, and drive-thru solution
MDVL stock closed a private placement of $50m on Monday and the share price has since risen 45%.
Medavail Holdings is enjoying trader momentum and is up a further 41% in pre-market trading sitting at $2.
Over the past year, Medavail Holdings Inc (MDVL) has traded between $0.79 and $14.59.
WD-40 Company (NASDAQ: WDFC)
WD-40 Company (NASDAQ: WDFC) reported its Q2 earnings yesterday. It cut its full-year profitability outlook on inflation pressure but also talked up its plans to raise prices. Investors are responding well as the WDFC share price climbs over 11% in pre-market trading.
The company also announced Steve Brass is going to be the next CEO of WD-40 Company. Steve will be the fifth CEO in WD-40’s 69-year history.
In Q2 the company reported net sales of $130m, up 16% Y/Y. The gross margin fell to 50% as input prices rose and it is focusing on restoring this to its target of 55%.
Net income came in at $19.5m, up 13% Y/Y.
Over the past year, WD-40 Company (WDFC) has traded between $170.44 and $321.41. Today it trades around $195.
Year-to-date, the WD-40 Company (WDFC) stock is down by -28.36% while the S&P 500 is down -6.18% over the same period of time.
Aterian (NASDAQ: ATER)
Aterian (NASDAQ: ATER) is a leading consumer product platform. It builds, acquires and partners with brands to create top-selling consumer products via its technology. On April 6 it was described as the 166th Fastest Growing Company in Americas by the Financial Times.
The ATER share price is up 55% in the past five days and another 16% in pre-market trading.
Nevertheless, Aterian stock has also been subject to a short squeeze. Over the past year, Aterian Inc (ATER) has traded between $2.10 and $32.
Biofrontera (NASDAQ: BFRI)
Biofrontera (NASDAQ: BFRI) stock is climbing in premarket trading. Investors appear to be pleased with BFRI’s Q4 and FY22 earnings report.
BFRI Financial Highlights
Q4 Total Revenues: $9.2m (up 7% Y/Y)
2021 Total Revenues: $24.1m (up 28% Y/Y)
Cash and cash equivalents: $24.5m as of December 31, 2021
Raised gross proceeds: $18m from IPO and $15m from private placement
The biopharmaceutical went public via IPO in October 2021. Its flagship product is Ameluz which is involved in various Phase 1, 2 and 3 studies for the treatment of actinic keratosis, a leading route to skin cancer.
Erica Monaco, Chief Executive Officer of Biofrontera Inc, said:
“2021 was a foundational year for Biofrontera Inc. From completing our IPO in October to laying the groundwork for expanding the label of our flagship product Ameluz®, I’m proud of the hard work by our team in executing Biofrontera’s strategic vision. We entered 2022 with the capital, commercial momentum and strategic plan in place to build shareholder value,”
ENDRA Life Sciences Inc (NASDAQ: NDRA)
ENDRA Life Sciences Inc (NASDAQ: NDRA) share price is up 30% in early market trading. The company reported its Q4 and full year earnings a week ago and has since gained 54%. But today’s bump appears to come from a positive analyst rating and research report.
Vernon Bernardino, of HC Wainwright, published a report with a Buy rating and target share price of $5.
Over the past year, ENDRA Life Sciences Inc (NDRA) has traded between $0.34 and $2.63. Today it sits at $0.59.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care.